COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment-Reference-Cited by-同舟云学术

COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

Published:2023-05-31 Issue: Volume:10 Page:46-52
ISSN:2283-5733
Container-title:Global & Regional Health Technology Assessment
language:
Short-container-title:Grhta

Author:

Canali Beatrice^ORCID,Candelora Laura^ORCID,Fiorentino Francesca^ORCID,Halmos Tom,La Malfa Paola^ORCID,Massara Francesca^ORCID,Vassallo Chiara^ORCID,Urbinati Duccio

Abstract

Background: Since the COVID-19 pandemic has placed more attention on drugs’ approval process and the importance of rapid decision-making in the healthcare sector, it is crucial to assess how time to market (TTM) of drugs varied. Objective: To estimate the impact of the COVID-19 pandemic on TTM of drugs in Italy. Methods: An IQVIA database was used to retrieve information on drugs that obtained positive opinion from the Committee for Medicinal Products for Human Use between January 2015 and December 2021. The available observations were divided into three groups (Pre COVID, Partially COVID, and Fully COVID) according to the timing of their negotiation process. Differences in average TTM among the three groups were analyzed in three steps: (1) descriptive statistics; (2) univariate analysis; (3) multivariate analysis, using a matching estimator. Results: A total of 363 unique combinations of molecule and indication met the inclusion criteria: 174 in the Pre COVID group, 69 in the Partially COVID group, and 123 in the Fully COVID group. Descriptive statistics and univariate analysis found a statistically significant difference in TTM among the three periods, with average TTM increasing during the pandemic (+136 days, p = 0.00) and then decreasing afterward (−23 days, p = 0.09). In the matching analysis, results for the Partially COVID period were confirmed (+108 days, p = 0.00) while results for the Fully COVID period lost significance but maintained a negative sign. Conclusions: The results suggest that after an adjustment phase in the Partially COVID period, a return to the status quo was reached.

Publisher

Aboutscience Srl

Subject

General Medicine

Reference17 articles.

1. Guidelines for pricing and reimbursement of medicines (determina DG/1372/2020) [Internet]. Agenzia Italiana del Farmaco; Available from: https://www.aifa.gov.it/en/-/l-aifa-approva-le-nuove-linee-guida-per-la-contrattazione-dei-prezzi-e-rimborsi-dei-farmaci (Accessed January 2023)

2. Commissioni consultive e tecnico-scientifiche [Internet]. Agenzia Italiana del Farmaco; Available from: https://www.aifa.gov.it/en/commissioni-tecnico-consultive (Accessed January 2023)

3. Criteri di valutazione dell’innovatività. Agenzia Italiana del Farmaco; Available from: https://www.aifa.gov.it/en/farmaci-innovativi (Accessed January 2023)

4. GU Serie Generale n.185 del 24-07-2020. Criteri e modalità con cui l’Agenzia italiana del farmaco determina, mediante negoziazione, i prezzi dei farmaci rimborsati dal Servizio sanitario nazionale. Available from: https://www.gazzettaufficiale.it/eli/id/2020/07/24/20A03810/sg (Accessed January 2023)

5. GU Serie Generale n.263 del 10-11-2012 - Suppl. Ordinario n. 201. Disposizioni urgenti per promuovere lo sviluppo del Paese mediante un più alto livello di tutela della salute. Available from: https://www.gazzettaufficiale.it/eli/id/2012/11/10/12A11988/sg (Accessed January 2023)